- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple myeloma
- Meeting Date: July 2019
- Public Summary Document (PSD) July 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) July 2019 PBAC Meeting - (Word 181KB)
Lenalidomide – July 2019
Lenalidomide: Capsule 5 mg, 10 mg, 15 mg; Revlimid®
Last updated
1 November 2019